Anavex Life Sciences Corp.
0HFR.L
London Stock Exchange2.70
USD
- -
- -
Anavex Life Sciences Corp.
0HFR.L
(London Stock Exchange)
Recent
price
2.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) develops novel small molecule therapeutics targeting the Sigma-1 receptor (SIGMAR1) via its proprietary SIGMACEPTOR discovery platform to treat central nervous system (CNS) diseases, including neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, neurodevelopmental conditions like Rett syndrome and Fragile X syndrome, neuropsychiatric disorders including schizophrenia, and undisclosed rare diseases; its lead candidate, ANAVEX 2-73 (blarcamesine), an oral SIGMAR1 agonist, has completed Phase 2a and Phase 2b/3 trials in early Alzheimer's disease, Phase 2 proof-of-concept in Parkinson's disease dementia, Phase 2 and Phase 3 studies in adult Rett syndrome patients, and Phase 2/3 in pediatric Rett syndrome patients, demonstrating potential disease-modifying effects on protein misfolding, mitochondrial dysfunction, autophagy, and neuroinflammation; additional pipeline assets include ANAVEX 3-71 (AF710B), a SIGMAR1 and M1 muscarinic receptor agonist advancing toward pivotal trials in schizophrenia following positive Phase 2 topline results in October 2025 showing safety, tolerability, and encouraging biomarker trends in electroencephalography and event-related potentials, with a new once-daily oral tablet formulation developed in October 2025; preclinical and clinical-stage compounds such as ANAVEX 1-41 and ANAVEX 1066 target neurodegenerative diseases, supported by precision medicine approaches using biomarkers like the ABCLEAR3 population and the newly identified COL24A1 gene for Alzheimer's efficacy. Founded in 2004 and headquartered at 630 Fifth Avenue, 20th Floor, New York, New York, the company operates primarily in the United States with international research ties originating in Greece, employing approximately 42 people and maintaining worldwide rights to its patent-protected candidates through 2030-2039. Recent developments include a November 2025 regulatory update announcing plans to request re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use negative trend vote on blarcamesine for early Alzheimer's after oral explanation feedback, peer-reviewed publications in August and September 2025 on blarcamesine's preventive effects in Alzheimer's models and autophagy mechanisms, September 2025 data confirming minimal cognitive decline in precision medicine Alzheimer's patients over 48 weeks, October 2025 long-term benefit findings versus natural history controls, presentations at the 18th Clinical Trials on Alzheimer's Disease conference in November 2025 and the 44th Annual J.P. Morgan Healthcare Conference in January 2026, and ongoing strategic partnership explorations with a cash runway exceeding three years as of November 2025.